« Return to News | Drug Sponsors

Sanofi signs deal with Glenmark

Monday, May 16, 2011 12:59 PM

France-based Sanofi has licensed a potential treatment for Crohn's disease from India's Glenmark Pharmaceuticals, according to Pharma Times.

The drug is now called GBR500 and is a monoclonal antibody to treat Crohn’s and other chronic autoimmune disorders. It is a first-in-class antagonist of the VLA-2 (alpha2-beta1) integrin.  GBR500 has completed a phase I study in the U.S. and the treatment has been well tolerated.

Glenmark will receive an upfront fee of $50 million; $25 million will be paid at the closing of the deal. The remainder is contingent upon Sanofi’s "positive assessment of certain data.” This data will be provided by Glenmark.

Glenmark could also receive success-based development, regulatory and commercial milestone payments worth over $600 million, plus royalties, says Pharma Times. Sanofi will get exclusive marketing rights in North America, Europe, Japan, Mexico, Argentina, Chile and Uruguay, and co-marketing or co-promotion rights in Brazil, Russia, Australia and New Zealand. Glenmark will retain rights in India and the rest of the world.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.